1
00:00:00,000 --> 00:00:03,300
Adding anagliptin lowered HbA1c by 0.57

2
00:00:03,300 --> 00:00:06,500
percentage points more than placebo in

3
00:00:06,500 --> 00:00:09,100
Korean adults.

4
00:00:09,100 --> 00:00:11,433
A randomised controlled trial evaluated

5
00:00:11,433 --> 00:00:13,467
adding anagliptin to metformin and

6
00:00:13,467 --> 00:00:16,533
empagliflozin in Korean adults.

7
00:00:16,533 --> 00:00:20,633
At Week 24, HbA1c fell by 0.81% with

8
00:00:20,633 --> 00:00:25,067
anagliptin versus 0.24% on placebo,

9
00:00:25,067 --> 00:00:29,733
differing by -0.57 percentage points (95%

10
00:00:29,733 --> 00:00:35,500
confidence interval -0.74 to -0.40).

11
00:00:35,500 --> 00:00:39,200
Enrolling 195 Korean adults over 24 weeks,

12
00:00:39,200 --> 00:00:43,033
adverse events affected 22.7% on anagliptin,

13
00:00:43,033 --> 00:00:46,233
with no reported hypoglycaemic events or

14
00:00:46,233 --> 00:00:48,167
deaths.

15
00:00:48,167 --> 00:00:50,400
The full report, its source and a free

16
00:00:50,400 --> 00:00:54,033
teaching slide are at diabesityrounds.com.
